Ann: MYX completes TherapeuticsMD product licensing transaction, page-27

Realistically not hard to see why shares have plateaued in spite of special dividend payout + company substantial buyback 18 Jan. further incentive for buying interest and maybe advance share value a bit before expected profit taking post div hopefully not too heavily sold down and risk leaving the door wide open for some opportunist predator entity interested in company's high earning potential from high end / high cost leased products made possible from money raised from Metrics sale . Mayne's reputation as an abysmally managed loss making company now under new unproven management we're been valued as such until there's solid evidence of company turnaround (not potential) not looked at through rose colored glasses , as of now company has no real tangible assets to speak of , yet to make net profit but real possibility of making net profit in 04 provided some of our costly leases perform well , share price should reflect that if we do .